We analyzed clinical and laboratory data of 220 adult patients with various forms of chronic hepatitis B virus (HBV) infection, who were admitted to the Gomel Regional Infectious Clinical Hospital in 2014–2019, and estimated the possibilities of their antiviral therapy. Currently, chronic HBV-infection is more common in the age group of 30–39 years (38.2 %), males predominate (74.1 %). Advanced liver fibrosis (stage F2 and higher) was in 41.1 % of patients, and liver cirrhosis – in 19.9 %. Most patients were HBeAg-negative (88.2 %), they had lower serum aminotransferase levels (p = 0.02) and DNA HBV viral load (p < 0.001) as compared with those HBeAg-positive. No significant differences in the age, liver fibrosis stages, HBV genotype between HBeAg-positive and HBeAg-negative patients have been found. The prevalence of HBsAg-negative (occult) chronic HBV-infection is 1.4 %, patients with occult HBV-infection may have progression of liver disease. HBV genotype distribution in patients with chronic HBV-infection is as follows: genotype D – 74.0 %, genotype A – 25.2 %, genotype C – 0.8 %. Drug-resistance mutations are observed only in patients previously treated with nucleos(t)ide analogues. Indications for antiviral treatment have 46.4 % of patients with chronic HBV-infection, and 23.6 % should be monitored for 3–6 months to determine the necessity of antiviral therapy. Tenofovir therapy is quite effective and safe, but requires an indefinitely long-term treatment and good adherence.
- 1. Гасич, Е. Л., Еремин В. Ф., Немира А. С. Генетическое разнообразие вируса гепатита В в Республике Беларусь // Здравоохранение. – 2016. – № 11. – С. 18–22.
- 2. Мицура, В. М., Волченко А. Н., Терешков Д. В., Запольская В. В. Распространенность и динамика заболеваемости различными формами гепатит В вирусной инфекции в Республике Беларусь // Клиническая инфектология и паразитология. – 2018. – Т. 7, № 3. – С. 370–380.
- 3. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection // Journal of Hepatology. – 2017. – Vol. 67. – P. 370–398.
- 4. Fattovich, G., Bortolotti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors // Journal of Hepatology. – 2008. – Vol. 48. – P. 335–352.
- 5. Lok, A. S., McMahon B. J., Brown R. S., Wong J. B. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis // Hepatology. – 2016. – Vol. 63. – P. 284–306.
- 6. Raimondo, G., Locarnini S., Pollicino T., Levrero M. et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection // Journal of Hepatology. – 2019. – Vol. 71. – P. 397–408.
- 7. Sarin, S. K., Kumar M., Lau G. K., Abbas Z. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update // Hepatology International. – 2016. – Vol. 10. – P. 1–98.
- 8. Squadrito, G., Spinella R., Raimondo G. The clinical significance of occult HBV infection // Annals of Gastroenterology. – 2014. – Vol. 27 (1). – P. 15–19.
- 9. Tong, S., Revill P. Overview of hepatitis B viral replication and genetic variability // Journal of Hepatology. – 2016. – Vol. 64. – P. 4–16.
- 10. WHO Global Hepatitis Report 2017. Geneva: World Health Organization.
- 11. WHO Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015. Geneva: World Health Organization.